Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Sandra, Milan"'
Autor:
Komal Jhaveri, Eric Paul Winer, Elgene Lim, Jose AlejandroPerez Fidalgo, Meritxell Bellet, Ingrid Alina Mayer, Valentina Boni, Jaymin M Patel, Aditya Bardia, Jose Manuel Garcia, Peter Kabos, Mary Gates, Ya-Chi Chen, Jill Fredrickson, Xiaojing Wang, Lori Sickels Friedman, Jill Spoerke, Steven Gendreau, Ciara Metcalfe, Lichuan Liu, Ching-Wei Chang, Sharareh Monemi, Monica Gonzalez, Ursula McCurry, Sandra Milan, Eric William Humke, Sherene Loi
Publikováno v:
Cancer Research. 80:PD7-05
Background: Modulation of estrogen activity and/or synthesis is a mainstay therapeutic strategy for ER+ breast cancer (BC). However, despite the effectiveness of available endocrine therapies, many patients ultimately relapse or develop resistance to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1e1023a79ddb1421636b8c4237ed234f
https://doi.org/10.1158/1538-7445.sabcs19-pd7-05
https://doi.org/10.1158/1538-7445.sabcs19-pd7-05
Autor:
Amy Banks, Pablo Garcia, Pierluigi Porcu, Lawrence D. Piro, Michael A. Caligiuri, Amy K. Ferketich, John P. Leonard, Don M. Benson, Lei Chen, Khuda D. Khan, Sandra Milan, Glenn C. Michelson, Christos Emmanouilides, John C. Byrd, Deborah Hurst, Charles F. Eisenbeis
Publikováno v:
Clinical Cancer Research. 12:7046-7053
Purpose: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c53a87335233ce96eb3184654124da
https://doi.org/10.1158/1078-0432.ccr-06-1571
https://doi.org/10.1158/1078-0432.ccr-06-1571
Autor:
Sandra Milan, Jon P. Gockerman, Kimberly Denis-Mize, Maurice J. Wolin, Alan Yuen, Alexandra Levine, William Larry Gluck, Susan E. Wilson, Mark A. Dayton, Barbara Tong, Dawn Navis, Jennifer Lucas, Deborah Hurst, Anita Difrancesco
Publikováno v:
Clinical Cancer Research. 10:2253-2264
Purpose: Expansion and activation of natural killer (NK) cells with interleukin-2 (IL-2) may enhance antibody-dependent cellular cytotoxicity (ADCC), an important mechanism of rituximab activity. Two parallel Phase I studies evaluated combination the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c4d345928d74f1162689730d391ea4e8
https://doi.org/10.1158/1078-0432.ccr-1087-3
https://doi.org/10.1158/1078-0432.ccr-1087-3
Autor:
William Larry, Gluck, Deborah, Hurst, Alan, Yuen, Alexandra M, Levine, Mark A, Dayton, Jon P, Gockerman, Jennifer, Lucas, Kimberly, Denis-Mize, Barbara, Tong, Dawn, Navis, Anita, Difrancesco, Sandra, Milan, Susan E, Wilson, Maurice, Wolin
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(7)
Expansion and activation of natural killer (NK) cells with interleukin-2 (IL-2) may enhance antibody-dependent cellular cytotoxicity (ADCC), an important mechanism of rituximab activity. Two parallel Phase I studies evaluated combination therapy with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7a26f8b39e42234dcba5d7ecdad20f9f
https://pubmed.ncbi.nlm.nih.gov/15073100
https://pubmed.ncbi.nlm.nih.gov/15073100
Publikováno v:
Blood. 104:4621-4621
Background: Antibody-dependent cellular cytotoxicty (ADCC) is an important mechanism of rituximab activity. Genetic polymorphisms in FcγRIIIa have been reported to influence response to rituximab in follicular non-Hodgkin’s lymphoma (NHL) patients
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e0caf7be041a62165e100431311c05c9
https://doi.org/10.1182/blood.v104.11.4621.4621
https://doi.org/10.1182/blood.v104.11.4621.4621